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Summary. Varicella zoster virus immediate-early (IE) proteins are intracellular regulators of viral gene 
expression. Some of them (IE62 and IE63) are found in large amounts in infected cells but are also 
components of the virion tegument. Several IE and early genes are transcribed during latency, while 
late genes are not. Recently, we demonstrated the presence of protein IE 63 in dorsal root ganglia of 
persistently infected rats as well as in normal human ganglia; other IE proteins have been found since 
in human ganglia. Cell-mediated immunity (CMI) to IE 62 has been evidenced. We found both 
humoral immunity and CMI to IE 63 in immune adults. In elderly zoster-free individuals, CMI to IE 63 
remained high. The differences in the CMI to IE 63 among young adults, elderly people and 
immunocompromized patients have to be analyzed according to their status relative to zoster, to 
determine whether the decrease in CMI, particularly to IE proteins, could be responsible for viral 
reactivation and for the onset of shingles. Hopefully, the waning of the CMI to VZV IE 63 and perhaps 
to other IE proteins could become a predictive marker for herpes zoster and reimmunization, not only 





Varicella zoster virus (VZV) has long been considered as a virus whose functioning could be deduced 
from that of herpes simplex virus (HSV), the prototype of Alphaherpesviruses, which is easy to 
produce in vitro and for which experimental models are available. Indeed VZV shares many 
morphological and biological properties with HSV and all other alphaherpesviruses. The most 
interesting characteristic certainly is the fact that, following primary infection, the virus can reach 
sensory ganglia and remain latent in the peripheral nervous system for many years before being 
reactivated and producing a rash, usually restricted to a single der-matoma. 
However, it is now obvious that the mechanisms involved in VZV latency and reactivation are not 
identical to and perhaps not even similar to those described for HSV. HSV-1 remains latent in neurons 
only, and its latency is characterized by the accumulation of antisense latency-associated transcripts 
(LATs) in the nucleus of infected cells. Although these transcripts are thought to contain at least one 
open reading frame, no corresponding protein has been detected so far and it is still not clear whether 
the LATs play a role in the induction or in the maintenance of latency, while they could be involved in 
viral reactivation [44]. These characteristics are shared by the other alphaherpesviruses such as 
pseudorabies virus, equine herpesvirus-1 or bovine herpesvirus-1 but not by VZV, whose genome lacks 
any homolog of the HSV LAT-encoding sequence. 
In situ hybridization and Northern blot analysis have provided evidence for a restricted transcription of 
the VZV genome during latency: both α (ORFs 4, 62 and 63) and putative β genes (ORFs 29 and 21) 
are transcribed during latency while no γ gene is [9-11, 31, 43]. The viral proteins corresponding to 
these transcripts have now been detected in rat [12] and in latently infected human ganglia [28, 30]. 
Three IE proteins (IE 4, 62 and 63) and two E proteins (ORF21p and ORF29p) accumulate in latently 
infected cells while no late protein seems to be expressed. 
 
 
Key roles of the immediate-early proteins in productive infection 
 
The VZV replication cycle can be subdivided into three phases: (1) virus adsorption and entry, (2) viral 
gene transcription and translation and (3) viral assembly and egress. Once the virus has penetrated the 
cell by fusion of its envelope with the plasma membrane, involving interactions between viral 
glycoproteins and cell receptors, the nucleocapsid reaches a nuclear pore through which the viral 
genome is released into the nucleoplasm. Viral genes are transcribed in the nucleus and transcripts are 
translated in the cytoplasm in three successive phases. A first wave leads to the very early expression 
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of ORFs 4, 61, 62 and 63, in the absence of de novo protein synthesis. The proteins produced, called 
immediate-early proteins (IE), migrate back into the nucleus and induce the expression of a second 
class of proteins called early (E), mainly the enzymes involved in viral DNA replication. The third and 
last wave of protein expression occurs after DNA replication and results in the synthesis of late (L) 
proteins that will constitute the viral particle. The capsids are assembled in the nucleus, wrapped 
around the newly replicated DNA before acquiring an envelope and being released. 
In this highly controlled process, the expression of the IE proteins is certainly the most critical step 
since these proteins play a key role in the regulation of expression of most other viral genes. Moreover, 
except for ORF6 lp, these proteins are found associated with purified virus particles [23, 24] and could 





ORF62p, a 175 kDa protein encoded by ORF 62 and also by ORF 71, is present in large amounts in the 
viral tegument [24] and thus brought in by the incoming virus. It is expressed as a nuclear IE 
phosphoprotein, thus it is called IE 62 and it exerts an important regulatory function in VZV 
replication, as evidenced by transient expression experiments demonstrating that it is capable of 
transactivating genes of all classes and increasing viral DNA infectivity [21, 38, 41]. Moreover, IE 62 
regulates its own promoter [5, 16]. However, these regulatory properties appear to be dose-dependent 
because IE 62 can positively or negatively regulate the expression of other genes, depending on its 
concentration. 
However, IE 62 does probably not act on its own, but in synergy with other IE proteins or even with 
cell proteins. A direct interaction with IE 4 specifically modifies the intracellular localization of the 
latter by transporting it to the nucleus [14]. Based on these data, it seems reasonable to propose that IE 
62, brought in at a low concentration by the incoming virus, initiates the IE phase by transacti-vating 
the expression of α genes. In a second step, IE 62 could participate in the activation of β genes and later 
of 7 genes. Due to its autoactivating properties, its intracellular concentration increases progressively 





ORF4p, a 55 kDa protein, is also present in large amounts in the viral tegument [23] and produced very 
early on in infected cells [13]. Its localization is mostly cytoplasmic but thanks to a direct interaction 
with IE 62, IE 4 can be transported to the nucleus [13]. IE 4 transactivates promoters of all three classes 
of genes, either on its own or in synergy with IE 62 [ 15], but it has no demonstrable transrepressing 






ORF63p is a 45 kDa phosphoprotein encoded by genes 63 and 72. It is a component of the viral 
tegument, shown to be a true IE protein and it is strongly expressed during lytic infection in cell culture 
as well as in skin lesions [12, 23, 34]. Its localization is mostly nuclear, but it can also be detected in 
the cytoplasm of infected cells [12]. Even though IE 63 shows a slight repression of IE 4 transac-
tivating properties on the IE 62 promoter [12], it lacks significant transactivating properties and its role 





The phosphoprotein encoded by ORF 61 (ORF61p, 62-65 kDa) has been considered as an IE protein 
only on the basis on its homology with HSV-1 ICP-0, but an experimental demonstration of its IE 
nature has not yet been provided. Contrary to the three other IE proteins, ORF61p does not belong to 
the viral tegument [23]. It enhances infectivity of VZV and HSV-1 DNA as shown by transient 
expression experiments [32] and, depending on its cellular concentration and on host cell lines, it can 
either repress or transactivate the functions of IE 4 and IE 62 on other VZV gene promoters [8, 32, 33]. 
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Besides their functional properties as regulatory proteins in productive infection, proteins IE 4, 62 and 
63 appear to be of great interest because they are also expressed in large amounts during latency. An 
expression of viral proteins has never been described during alphaherpesvirus latency, but it has been 
demonstrated for IE 63, first in an animal model [12, 39] then in humans [30]. Later, other IE or E 
proteins have been detected in latently infected human cells [28]. Mostly intranuclear during 
productive infection according to their functions, these proteins are detected predominantly in the 
cytoplasm of latently infected cells but they become detectable in nuclei when the virus reactivates. 
The reasons for this modified distribution during latency are still not understood. It is also not clear 
whether cytoplasmic sequestration is the result of a failed process that normally carries them to the 
nucleus where they perform their regulatory tasks or whether their accumulation by itself inhibits 
replication. Cytoplasmic overloading of these proteins during latency suggests new hypotheses for the 
establishment and maintenance of VZV latency [27]: the virus enters the cell as in productive infection 
and the cycle initiates by the expression of some of the regulatory IE proteins (IE 4, 62 and 63) which 
probably migrate to the nucleus to exert their regulatory functions, but they are in such low quantities 
that they remain undetectable. 
Even a low amount of IE proteins migrating to the nucleus allows the expression of E proteins encoded 
by ORFs 21 and 29 [28], which also accumulate in large amounts in the cytoplasm. It is not known 
whether other E proteins are expressed and whether viral DNA replication occurs at all, but so far, no L 
protein has been detected during latency. 
The mechanisms involved in this process have yet to be identified, but it is tempting to conclude that 
cells in which the virus becomes latent lack the necessary elements to process IE proteins and to give 
them the conformation by which they become functional. Phosphorylation or other post-translational 
modifications are candidate impaired process mechanisms. It is also possible that some cellular 
components interact with viral proteins or with viral promoters that can interfere with the replication 
cycle and lead to replicative arrest. For instance, Patel and collaborators have demonstrated that the 
isoforms of the cellular transcription factor Oct-2 expressed specifically in neuronal cells can inhibit 
basal activity of the VZV IE 62 promoter in neuronal cells but not in other cell types, suggesting a cell 
type-specificity [35]. This mechanism could be of particular importance for the onset of VZV latency 
in sensory ganglia. 
However, such explanations still need experimental confirmation and must take into account the 
observation that inhibition is reversible in yet undetermined conditions when reactivation occurs. 
Another important difference between VZV and HSV latency is the nature of the cells in which the 
virus remains latent. HSV clearly resides in neurons only whereas the precise localization of persistent 
VZV is still debated: using in situ hybridization or in situ PCR, evidence of latency in neuronal cells 
[17, 20], in non neuronal cells [11, 31] or in both cell types [26, 29] has been shown. Animal models 
did not allow elucidation of this issue because in mice and rats the viral genome was detected in both 
cell types [39, 45]. 
 
 
Immunogenicity of the IE proteins 
 
One of the parameters of obvious importance for the control of virus infection is host immunity. 
Clinical observations have shown that the frequency and severity of viral reactivations increase in 
patients whose cell-mediated immunity (CMI) is impaired because of age, pathological disorders or 
immunosuppressive treatments prior to transplantation [3, 6, 18]. 
Previous studies have shown that viral tegument proteins, including IE 62 and 63, and the major 
glycoproteins, are important targets for CMI to VZV. They elicit a long term humoral and cellular 
immune response after natural VZV infection [1,4, 40]. T lymphocytes from most VZV naturally 
immune donors proliferate in vitro after stimulation with these proteins and they can lyse autologous 
target cells that express IE 62, 63, gC, gE, gG or gl. 
The critical role of immune control has been suggested by Hope-Simpson as early as 1965 [19]: VZV 
primary infection appears to be limited by host "resistance" (immune response) that remains high for 
many years, with a slow decrease over time. This decrease could, however, be partly counterbalanced 
by frequent viral reactivations or contact with infected individuals, which would contribute to 
maintaining an efficient immunity until reaching a critical level under which the host resistance would 
be too low to control viral reactivation. This hypothesis, based only on clinical observations is still 
valid today even if it appears now that it is mostly the CMI that limits viral reactivation. Indeed, virus 
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reactivates in spite of high anti-VZV antibody titers and the zoster episode is not correlated with 
hypogammaglobulinsemia. 
It is tempting to think that the expression of viral proteins in latently infected cells constitutes another 
way to trigger the immune response and could thus contribute to maintain it at a protective level. In this 
context, it will be of interest to characterize the immune response to viral proteins expressed during 
latency, in the elderly and in immunocompromised patients who have a high incidence of herpes zoster. 
It is well known that the CMI is often impaired with age, as documented using in vitro PBMC 
stimulation by whole VZV antigens [18]. Such a study has not been performed with purified VZV 
proteins and in particular with proteins expressed in latently infected cells. 
However, many questions are raised by this hypothesis of a role for the viral 'latency proteins' in 
maintaining a specific immune response. The nervous system is indeed protected from immune 
recognition by anatomical barriers and neurons lack classical MHC molecules at their surfaces . On the 
contrary, satellite cells surrounding neurons express MHC and they could play an important role in 
antigen presentation. It is thus critical to define clearly in which cells the virus remains quiescent. So 
far, during latency, IE 63 has been observed only in neuron cytoplasms. If neurons are the only cells 
expressing viral antigens, the mechanisms leading to the recognition of viral peptides must be clarified. 
It is possible that non-classical MHC proteins are being expressed at the cell surface in response to 
viral infection, as it has been suggested for HSV [36]. However, in HSV-infected cells, peptide 
presentation by MHC molecules appears to be impaired because of a viral protein that inhibits peptide 
processing [22, 42]. VZV has been shown to selectively downregulate cell-surface MHC class I 
expression on human fibroblast cells and to inhibit IFN-7 induction of MHC class II cell surface 
expression [2]. 
Enhancing the immune response to IE 63 may become an important strategy for preventing VZV 
reactivation from latency. If so, IE 63 could be a suitable candidate as an additive for a VZV vaccine to 
be given to ageing adults in order to boost their immunity and to prevent herpes zoster [7, 25]. 
Because recognition by the immune system of proteins expressed during latency, proteins such as IE 62 
and 63, could play a role in the control of latency, it must be documented using animal models or by 
studies involving a larger number of donors, particularly donors with a high probability of reactivation 
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